GlassScriptPhysician profile
Crystal Lea Mathis
NPI 1689339756
$2,152.02
in general payments reported to CMS, 2019-2025
22 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 97% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $36.03 · 2024: $960 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,977 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.98 |
| Education | $175.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $308.60 | 2024-2025 | Slynd, Twirla |
| Astellas Pharma US INC | $280.04 | 2024-2025 | Veozah |
| Biogen, INC. | $198.34 | 2024-2025 | Zurzuvae, Vumerity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.99 | 2024 | Xifaxan |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.98 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.57 | 2025 | |
| Corcept Therapeutics | $111.77 | 2024 | Korlym |
| Krystal Biotech INC | $110.43 | 2024 | Vyjuvek |
| Teva Pharmaceuticals USA, INC. | $108.16 | 2024 | Austedo Xr |
| Lilly USA, LLC | $107.34 | 2024 | Zepbound |
| Shield Therapeutics INC | $99.53 | 2024 | |
| Mayne Pharma Commercial LLC | $81.53 | 2025 | |
| Organon LLC | $63.72 | 2024-2025 | Nexplanon |
| Millicent US INC | $53.54 | 2024-2025 | Femlyv, Intrarosa |
| Vertex Pharmaceuticals Incorporated | $51.10 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.15 | 2025 | |
| Hologic Sales and Service, LLC | $36.08 | 2024-2025 | Myosure Tissue Removal Device |
| Dexcom, INC. | $36.03 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $35.12 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $25.43 | 2025 | Exparel |
| Evofem Biosciences, INC. | $20.19 | 2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $16.38 | 2025 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.